PBAC's latest decision on Paclitaxel: Recommended with restriction (2006). Considered for adjuvant treatment of node positive breast cancer irrespective of oestrogen receptor status, administered sequentially to doxorubicin and cyclophosphamide.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
early breast cancer patients who have had surgery and are node positive
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Disease-free survival, Overall survival
Key trials
CALGB 9344, NSABP B-28
Comparator
no sequential therapy following standard chemotherapy with doxorubicin hydrochloride and cyclophosphamide (AC)